Physician profile
Haeley E Harman
NPI 1205933538
$6,739.91
in general payments reported to CMS, 2019-2025
33 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,876 · 2020: $890 · 2021: $1,358 · 2022: $1,199 · 2023: $492 · 2024: $703 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,416.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $862.32 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $814.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $796.04 | 2019-2024 | Otezla, Repatha |
| Abbvie INC. | $769.86 | 2021-2025 | |
| Allergan, INC. | $509.24 | 2019-2020 | |
| Astellas Pharma US INC | $327.45 | 2019-2023 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.38 | 2019-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $305.40 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $257.26 | 2019-2022 | |
| Amarin Pharma, INC. | $219.38 | 2019-2022 | |
| Pfizer INC. | $219.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $208.77 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.15 | 2019-2022 | |
| Glaxosmithkline, LLC. | $188.92 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $146.78 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $136.02 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $63.18 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.93 | 2021-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $39.90 | 2022-2023 | Eliquis |
| Daiichi Sankyo INC. | $39.72 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $38.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.45 | 2022 | |
| Avanir Pharmaceuticals, INC. | $34.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.00 | 2022 | |
| Esperion Therapeutics, INC. | $23.90 | 2021 | |
| Merck Sharp & Dohme LLC | $23.51 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.95 | 2024 | Voquezna |
| Eisai INC. | $15.85 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $14.29 | 2019 | |
| Shield Therapeutics INC | $14.24 | 2023 | Accrufer |
| Abbott Laboratories | $12.87 | 2023 | Freestyle Libre 3 |
| Nalpropion Pharmaceuticals LLC | $11.74 | 2019 | |
| Dynavax Technologies Corporation | $10.55 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haeley Harman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.